Ameriprise
RLMD icon

Ameriprise’s Relmada Therapeutics RLMD Stock Holding History

Ameriprise’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
1,937,972
+347,026
+22% +$2.42M ﹤0.01% 1831
2026
Q1 		$11.1M Sell
1,590,946
-329,153
-17% -$1.56M ﹤0.01% 1856
2025
Q4 		$9.27M Buy
+1,920,099
New +$6.43M ﹤0.01% 1971

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's RLMD Position: Q2 2026 in Review

Ameriprise increased its Relmada Therapeutics (RLMD) stake by 22% in Q2 2026, buying an estimated $2.42M and bringing the position to 1,937,972 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1831.

Ameriprise first reported a position in RLMD in Q4 2025 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Ameriprise held 1,937,972 shares of Relmada Therapeutics worth $13.4M as of Q2 2026.
  • Ameriprise bought 347,026 Relmada Therapeutics shares in Q2 2026, an estimated $2.42M.
  • Relmada Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1831 holding.
  • Ameriprise first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.